Valuation: TAUNS Laboratories,Inc.

Market Cap 50.57B 309M 271M 252M 232M 435M 29.75B 442M 3B 1.17B 14.63B 1.16B 1.13B P/E 2025
8.67x
P/E 2026 * 9.53x
Enterprise Value 57.4B 351M 308M 286M 263M 494M 33.77B 501M 3.4B 1.33B 16.6B 1.32B 1.29B EV / Sales 2025
3.23x
EV / Sales 2026 * 3.97x
Free-Float
29.89%
Yield 2025
5.2%
Yield 2026 * 7.44%
1 day-0.21%
1 week-2.07%
Current month+0.42%
1 month-2.67%
3 months-2.67%
6 months-11.40%
Current year-6.88%
1 week 473
Extreme 473
489
1 month 463
Extreme 463
493
Current year 463
Extreme 463
568
1 year 463
Extreme 463
603
3 years 401
Extreme 401
733
5 years 401
Extreme 401
733
10 years 401
Extreme 401
733
Manager TitleAgeSince
Chief Executive Officer 51 30/04/2014
Director of Finance/CFO 66 31/10/2018
Corporate Officer/Principal 39 30/06/2022
Director TitleAgeSince
Director/Board Member 51 30/04/2014
Director/Board Member 66 31/08/2020
Director/Board Member 53 31/03/2016
Change 5-day change 1-year change 3-year change Capi.($)
-0.21%-2.07%-9.71% - 309M
-1.91%-5.48%+231.67%+279.77% 19.54B
+1.30%-4.25%-44.21%-26.73% 9.39B
+1.05%-2.57%+43.73%+24.79% 6.82B
-3.72%+5.78%+227.92%-23.97% 5.87B
+1.38%+7.00%-15.41%-21.33% 5.61B
-0.83%-5.88%-47.46% - 4.39B
-8.03%-14.67%+71.70%+90.15% 4.19B
-0.12%-3.72%-26.25%-30.14% 4.03B
-2.24%-2.39%-21.94%-44.41% 2.66B
Average -1.33%-2.51%+41.00%+31.02% 6.28B
Weighted average by Cap. -1.21%-3.03%+88.97%+90.56%

Financials

2025 2026 *
Net sales 19.06B 116M 102M 95.11M 87.27M 164M 11.21B 167M 1.13B 441M 5.51B 437M 428M 14.76B 90.14M 79.17M 73.63M 67.56M 127M 8.68B 129M 874M 342M 4.27B 338M 331M
Net income 6.5B 39.71M 34.87M 32.43M 29.76M 55.92M 3.82B 56.78M 385M 150M 1.88B 149M 146M 5.2B 31.77M 27.91M 25.95M 23.82M 44.75M 3.06B 45.44M 308M 120M 1.5B 119M 117M
Net Debt 6.83B 41.72M 36.64M 34.08M 31.27M 58.75M 4.02B 59.66M 405M 158M 1.98B 157M 153M 7.99B 48.83M 42.89M 39.89M 36.6M 68.77M 4.7B 69.83M 474M 185M 2.31B 183M 179M
Logo TAUNS Laboratories,Inc.
Tauns Laboratories Inc is a Japan-based company engaged in the business of developing, manufacturing and marketing in vitro diagnostic products and research reagents. The Company operates its business in the in vitro diagnostic products business segment. The Company’s main product is antigen test kit that uses immunochromatography to enable rapid diagnosis at the patient's side without the need for special equipment. The products include ImunoAce Flu, ImunoAce SARSCoV-2 II, ImunoAce SARSCoV-2 Saliva, ImunoAce SARSCoV-2/Flu, ImunoAce Adeno, ImunoAce Strep A Neo, ImunoAce hMPV, ImunoAce Mycopiasma, ImunoAce RSV Neo and ImunoAce Noro.
Employees
218
Date Price Change Volume
24/07/26 JP¥474.00 -0.21% 335,200
23/07/26 JP¥475.00 -0.21% 151,400
22/07/26 JP¥476.00 -1.04% 610,100
21/07/26 JP¥481.00 -0.62% 315,600
17/07/26 JP¥484.00 -0.82% 329,000
Trader
Investor
-
Global
-
Quality
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
UNDERPERFORM
Number of Analysts
2
Last Close Price
474.00JPY
Average target price
420.00JPY
Spread / Average Target
-11.39%

Annual profits - Rate of surprise

  1. Stock Market
  2. Stocks
  3. 197A Stock